<VariationArchive RecordType="classified" VariationID="583756" VariationName="NC_000016.10:g.(?_2081589)_(2088616_?)del" VariationType="Deletion" Accession="VCV000583756" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-11-05" DateCreated="2018-10-10" MostRecentSubmission="2018-10-10">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="567474" VariationID="583756">
      <GeneList>
        <Gene Symbol="TSC2" FullName="TSC complex subunit 2" GeneID="7249" HGNC_ID="HGNC:12363" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="2047985" stop="2089491" display_start="2047985" display_stop="2089491" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="2097989" stop="2138712" display_start="2097989" display_stop="2138712" Strand="+" />
          </Location>
          <OMIM>191092</OMIM>
          <Haploinsufficiency last_evaluated="2020-06-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TSC2">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-06-10" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=TSC2">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000016.10:g.(?_2081589)_(2088616_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" innerStart="2081589" innerStop="2088616" display_start="2081589" display_stop="2088616" variantLength="7028" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" innerStart="2131590" innerStop="2138617" display_start="2131590" display_stop="2138617" variantLength="7028" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.10" sequenceAccession="NC_000016" sequenceVersion="10" change="g.(?_2081589)_(2088616_?)del" Assembly="GRCh38">
            <Expression>NC_000016.10:g.(?_2081589)_(2088616_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.(?_2131590)_(2138617_?)del" Assembly="GRCh37">
            <Expression>NC_000016.9:g.(?_2131590)_(2138617_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000016.10:g.(?_2081589)_(2088616_?)del AND Tuberous sclerosis 2" Accession="RCV000708025" Version="1">
        <ClassifiedConditionList TraitSetID="3366">
          <ClassifiedCondition DB="MedGen" ID="C1860707">Tuberous sclerosis 2</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-02-21" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-02-21" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2018-10-10" MostRecentSubmission="2018-10-10">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17287951</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24789117</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3366" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6897" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Tuberous sclerosis 2</ElementValue>
                <XRef ID="Tuberous+sclerosis%2C+type+2/7257" DB="Genetic Alliance" />
                <XRef ID="MONDO:0013199" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">TSC2</ElementValue>
                <XRef Type="MIM" ID="613254" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="5381" />
                <XRef ID="5381" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">Tuberous sclerosis complex (TSC) involves abnormalities of the skin (hypomelanotic macules, confetti skin lesions, facial angiofibromas, shagreen patches, fibrous cephalic plaques, ungual fibromas); brain (subependymal nodules, cortical tubers, and subependymal giant cell astrocytomas [SEGAs], seizures, intellectual disability / developmental delay, psychiatric illness); kidney (angiomyolipomas, cysts, renal cell carcinomas); heart (rhabdomyomas, arrhythmias); and lungs (lymphangioleiomyomatosis [LAM], multifocal micronodular pneumonocyte hyperplasia). Central nervous system tumors are the leading cause of morbidity and mortality; renal disease is the second leading cause of early death.</Attribute>
                <XRef ID="NBK1220" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301399</ID>
                <ID Source="BookShelf">NBK1220</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="Orphanet, 2007">
                <URL>https://www.orpha.net/data/patho/Pro/en/Emergency_TuberousSclerosis.pdf</URL>
                <CitationText>Orphanet, Tuberous sclerosis, 2007</CitationText>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23788249</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG, 2013">
                <ID Source="PubMed">23519317</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2015">
                <ID Source="PubMed">25356965</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG, 2016">
                <ID Source="PubMed">27854360</ID>
                <ID Source="DOI">10.1038/gim.2016.190</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="Recommendation" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <XRef ID="805" DB="Orphanet" />
              <XRef ID="C1860707" DB="MedGen" />
              <XRef ID="MONDO:0013199" DB="MONDO" />
              <XRef Type="MIM" ID="613254" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1609160" SubmissionDate="2018-08-29" DateLastUpdated="2018-10-10" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="3625534|MedGen:C1860707" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000837135" DateUpdated="2018-10-10" DateCreated="2018-10-10" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-02-21">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">17287951</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24789117</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exons 31-42 of the TSC2 gene. The 5' boundary is likely confined to intron 30. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. A similar deletion of exons 31-42 (also known as exons 30-41 in the literature) has been reported in individuals affected with tuberous sclerosis complex (PMID: 17287951). Many different truncations downstream of this variant have been reported to be pathogenic, including a frameshift variant, c.5405_5408dup (p.Phe1803Leufs*42), that has been reported as a disease-causing de novo variant in an individual affected with tuberous sclerosis complex (PMID: 24789117). This suggests that deletion of this region of the TSC2 protein is causative of disease. For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="TSC2" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.(?_2131590)_(2138617_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Tuberous sclerosis 2</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C1860707" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB4474525</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1609160" TraitType="Disease" MappingType="Name" MappingValue="Tuberous sclerosis 2" MappingRef="Preferred">
        <MedGen CUI="C1860707" Name="Tuberous sclerosis 2" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

